Dana-Farber Cancer Institute faculty served as past Presidents of ASCO: Emil Frei, MD, 1968-69, George P. Canellos, MD, 1993-94, Karen H. Antman, MD, 1994-95, Robert Mayer, MD, 1997-98, Bruce Johnson, MD 2017-18, Monica Bertagnolli, MD, 2018-19.
Immunotherapy Combination Shows Benefit for Patients with Advanced Melanoma, Phase 3 Trial Shows
A combination of two drugs that target different proteins on immune system T cells kept advanced melanoma in check significantly longer than one of the drugs alone in a phase 3 clinical trial involving 714 patients. Dana-Farber Cancer Institute investigators co-led the study. Findings will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually June 4-8, 2021, and are included in the ASCO press program.
Dana-Farber Researchers Present Key Studies at ASCO Annual Meeting
Dana-Farber Cancer Institute researchers are presenting dozens of research studies at the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO). The studies will be presented during the virtual program on June 4-8, 2021. ASCO is the world’s largest clinical cancer research meeting, attracting more than 30,000 oncology professionals from around the world.
ASCO Featured Oral Presentations
The Annual Meeting of the American Society of Clinical Oncology (ASCO) will take place virtually June 4-8th. To keep-up with latest advances, view or download the live schedule of oral presentations by Dana-Farber.
Dana-Farber Cancer Institute Faculty Recognized as 2021 ASCO Leaders in Cancer Care
The American Society of Clinical Oncology (ASCO) recognized two Dana-Farber Cancer Institute researchers as winners of ASCO's Special Awards, the Society’s highest honors. The recipients of these awards have worked to transform cancer care around the world.
Eric P. Winer Elected ASCO President for Term Starting in June 2022
The American Society of Clinical Oncology (ASCO) has elected Eric P. Winer, MD, to serve as its President for the term beginning in June 2022. He will take office as President-Elect during the ASCO Annual Meeting in June 2021. Winer is the chief clinical development officer, senior vice president for medical affairs, chief of the Division of Breast Oncology, and the Thompson Chair in Breast Cancer Research at Dana-Farber Cancer Institute. He is also a professor of medicine at Harvard Medical School.
Immunotherapy Drug Delays Recurrence in Kidney Cancer Patients
Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of a phase 3 clinical trial of adjuvant immunotherapy in this patient population.
Keywords: ASCO